Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92825 | 0.83 | CHRNB4 (0.35) | ALDH1A1 | |
| SCHEMBL2759554 | 0.79 | L3MBTL1 (0.38) | NPSR1ALDH1A1L3MBTL1LMNAHTT | |
| SCHEMBL9911480 | 0.76 | CA1 (0.44) | NPSR1ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL13768117 | 0.76 | USP2 (0.33) | NPSR1L3MBTL1LMNAHTTSMN1; SMN2 | |
| SCHEMBL13764332 | 0.74 | GAA (0.31) | NPSR1ALDH1A1L3MBTL1LMNAHTT | |
| SCHEMBL13812295 | 0.74 | ALDH1A1 (0.39) | NPSR1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13764329 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL21885778 | 0.72 | KDM4E (0.34) | ALDH1A1L3MBTL1 | |
| SCHEMBL3220299 | 0.70 | KMT2A (0.45) | NPSR1ALDH1A1L3MBTL1LMNAHTT | |
| SCHEMBL84558 | 0.68 | ALDH1A1 (0.38) | NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| US-20160130300-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-05-12 | — | — | US | disclosed |
| US-7524864-B2 | Methods of treating sleep disorders | HYPNION, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524864-B2 | Methods of treating sleep disorders | HYPNION, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7494998-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7494998-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | HYPNION, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | GABRB3, GRIN2C, GABRB2 | NPSR1 86/4885ALDH1A1 1166/4885L3MBTL1 2252/4885 |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | GABRA5, GABRE, HCRTR2 | NPSR1 348/4885ALDH1A1 1099/4885L3MBTL1 4527/4885 |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | GABRA5, HCRTR2, HCRTR1 | NPSR1 205/4885ALDH1A1 1540/4885L3MBTL1 4536/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | NPSR1 3244/4885ALDH1A1 112/4885L3MBTL1 4486/4885 |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | NPSR1 3244/4885ALDH1A1 112/4885L3MBTL1 4486/4885 |
| US-10335409-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | NPSR1 3244/4885ALDH1A1 112/4885L3MBTL1 4486/4885 |
| US-20160130300-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | NPSR1 3244/4885ALDH1A1 112/4885L3MBTL1 4486/4885 |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | NPSR1 3899/4885ALDH1A1 200/4885L3MBTL1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.